Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06606288 · ClinicalTrials.gov registry record
Characterizing Outcomes and Real-World Experience of Cardiac Physiologic Pacing (The CORE-CPP Study)
A clinical trial of Heart Failure, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Active
- Registry status
- 6,000
- Enrollment target
- 1
- Study location
NCT06606288: Active study of Heart Failure, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
NCT06606288 is a study of Heart Failure that is active but no longer recruiting, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 6,000 participants, above the 2,034-participant average among 397 other Heart Failure trials with a reported enrollment target (195% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06606288, a study of Heart Failure, is active but no longer recruiting, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- ACTIVE NOT RECRUITING
- Registry status
- 6,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to use real-world evidence to validate that conduction system pacing (CSP), delivered via a Medtronic 3830 catheter-delivered lead and a Medtronic dual-chamber transvenous pacemaker, is a safe and effective alternative to biventricular pacing (BVP) in patients indicated for cardiac resynchronization therapy (CRT) to deliver cardiac physiologic pacing (CPP), as documented in the clinical literature.
Primary Outcome
Demonstrate that dual-chamber CSP is non-inferior to BVP on implant safety in patients indicated for CRT. Endpoint: Compare the acute (≤ 30 days) overall complication rate associated with dual chamber CSP vs. BVP. The acute overall complication rate is a composite measure of separate elements of complications (embolism and thrombosis, events at puncture site, cardiac effusion and perforation, device-related complications, and other procedural complications) and reinterventions (lead-related rei
Conditions Studied
Interventions
- DEVICE Conduction system pacing
- DEVICE Bi-ventricular pacing
Study Locations (1)
Minnesota
- Medtronic - Mounds View
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,000 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2030-12-31 |
What the registry record for NCT06606288 still lists
NCT06606288 is an observational study that tracks outcomes without assigning an intervention. Its 6,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,034-participant average among 397 other Heart Failure trials with a reported enrollment target (195% higher).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Conduction system pacing is the first listed.
NCT06606288 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06606288 about?
NCT06606288 is a clinical study titled "Characterizing Outcomes and Real-World Experience of Cardiac Physiologic Pacing (The CORE-CPP Study)". The purpose of this study is to use real-world evidence to validate that conduction system pacing (CSP), delivered via a Medtronic 3830 catheter-delivered lead and a Medtronic dual-chamber transvenous pacemaker, is a safe and effective alternative to biventricular pacing (BVP) in patients indicated ...
What is the current status of trial NCT06606288?
This trial is currently active not recruiting. The enrollment target is 6,000 participants. The study started on 2017-01-01. Estimated completion is 2030-12-31.
What conditions does trial NCT06606288 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT06606288?
The interventions under investigation include: Conduction system pacing (DEVICE), Bi-ventricular pacing (DEVICE).
Who is sponsoring clinical trial NCT06606288?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06606288 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06606288's enrollment target sits among peer trials
6,000 12th of 397 higher than 385 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- NCT00280202 · 6,000 participants
Detection of Genetic Markers of Lung Cancer
- NCT03127631 · 6,000 participants · NA
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
- NCT03539705 · 6,000 participants
Food Allergy Registry at a Single Site
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI